Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-16

Reporting Person: MORE ROBERT J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-16	Common Stock	C	1944443	—	Acquired	1944443	Indirect
2019-10-16	Common Stock	C	60822	—	Acquired	60822	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-16	Series A-1 Convertible Preferred Stock	$	C	1666666	Disposed		Common Stock (1666666)	Indirect
2019-10-16	Series A-2 Convertible Preferred Stock	$	C	60822	Disposed		Common Stock (60822)	Direct
2019-10-16	Series B Convertible Preferred Stock	$	C	277777	Disposed		Common Stock (277777)	Indirect

Footnotes

F1: Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.